A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer

James Dan Mellor, Michael Brown, Helen Ruth Irving, John Raymond Zalcberg, Alex Dobrovic

Research output: Contribution to journalArticleResearchpeer-review

174 Citations (Scopus)

Abstract

Antibody-dependent cellular cytotoxicity (ADCC) is a major mechanism of action of therapeutic monoclonal antibodies (mAbs) such as cetuximab, rituximab and trastuzumab. Fc gamma receptors (FcgR) on human white blood cells are an integral part of the ADCC pathway. Differential response to therapeutic mAbs has been reported to correlate with specific polymorphisms in two of these genes: FCGR2A (H131R) and FCGR3A (V158F). These polymorphisms are associated with differential affinity of the receptors for mAbs. This review critically examines the current evidence for genotyping the corresponding single nucleotide polymorphisms (SNPs) to predict response to mAbs in patients with cancer.
Original languageEnglish
Article number1
Pages (from-to)1 - 10
Number of pages10
JournalJournal of Hematology & Oncology
Volume6
DOIs
Publication statusPublished - 2013

Cite this